SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-003063
Filing Date
2022-03-08
Accepted
2022-03-08 07:41:54
Documents
14
Period of Report
2022-03-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20220302.htm   iXBRL 8-K 68450
2 EX-99.1 inzy-ex99_1.htm EX-99.1 24646
3 GRAPHIC img4202433_0.jpg GRAPHIC 8171
  Complete submission text file 0000950170-22-003063.txt   241843

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20220302_pre.xml EX-101.PRE 11575
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20220302_lab.xml EX-101.LAB 18213
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20220302.xsd EX-101.SCH 2487
8 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20220302_htm.xml XML 4881
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 22720343
SIC: 2834 Pharmaceutical Preparations